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ABSTRACT
COVID-19, the disease caused by the SARS-CoV-2 virus, has been declared a
pandemic by the World Health Organization, with over 294,000 cases as of March
22, 2020 (WHO, 2020). In this review, we present an overview of recent studies
using Machine Learning and, more broadly, Artificial Intelligence, to tackle many
aspects of the COVID-19 crisis at different scales including molecular, medical
and epidemiological applications. We finish with a discussion of promising future
directions of research and the tools and resources needed to facilitate AI research.
Executive Summary
• There is a broad range of potential applications of AI covering medical and societal chal-
lenges created by the COVID-19 pandemic; however, few of them are currently mature
enough to show operational impact.
• AI can support COVID-19 diagnosis from medical imaging, provide alternative ways to
track disease evolution using non-invasive devices, and generate predictions on patient out-
comes based on multiple data inputs including electronic health records (EHR).
• From a molecular perspective, AI can be used to estimate the structure of SARS-CoV-2-
related proteins, to identify existing drugs that may be repurposed to treat the virus, and to
propose new compounds that may be promising for drug development.
• AI modelling has been applied in several areas of epidemiological research, including fore-
casting the number of new confirmed case given different public policy choices and mod-
elling the rate of asymptomatic cases.
• In light of the vast amounts of information being generated and shared, AI can help investi-
gate the scale and spread of the “infodemic”, as well as specifically address the propagation
of misinformation.
• Sharing and hosting data and models, whether they be medical, molecular, or scientific, is
critical to accelerate the development and operationalization of AI to support the response
to the COVID-19 pandemic.
• International cooperation based on multidisciplinary AI research and open science can help
to prepare the regions of the world which have not yet experienced widespread outbreaks.
∗equal contribution
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1 INTRODUCTION
With the continued growth of the COVID-19 pandemic, researchers worldwide are working to bet-
ter understand, mitigate and suppress its spread. Key areas of research include studying COVID-19
transmission, facilitating its detection, developing possible vaccines and treatments, and understand-
ing the socio-economic impacts of the pandemic. In this article, we discuss how Artificial Intelli-
gence can contribute to these goals by enhancing all of these different activities, improving the
efficiency and speed of existing approaches as well as proposing original lines of research. We have
conducted an extensive review of the rapidly emerging literature and identified specific applications
of AI at three different scales: the molecular scale, including drug discovery-related research; the
medical scale, including individual patient diagnosis and treatment; and the societal scale, including
epidemiological and infodemic research. We also review open-source datasets and resources that
are available to facilitate the development of AI solutions.
The purpose of this review is not to evaluate the impact of the described techniques, nor to recom-
mend their use, but to show the reader the extent of existing applications and to provide an initial
picture and road map of how AI could help the global response to the COVID-19 pandemic. We
note that the scope of this review is restricted to applications of Machine Learning (ML) and Arti-
ficial Intelligence (AI), and that we have therefore made judgement calls regarding whether certain
methodologies fall into this category. For example, we have included applications where authors
have explicitly described the use of models such as neural networks and decision trees, while ex-
cluding applications based on regression. Furthermore, we note that many of the articles cited are
still pre-prints at the time of writing this review; given the fast-moving nature of the crisis we strove
to be comprehensive in our coverage, but their full scientific rigour should still be assessed by the
scientific community through peer-reviewed evaluation and other quality control mechanisms. For
specificity, we signify all preprints with † .
2 PATIENT SCALE: FROM DIAGNOSIS TO OUTCOME PREDICTIONS
To date, most clinical applications of AI to the COVID-19 response have focused on diagnosis
based on medical imaging. In recent literature, we have found several works that use AI to support
diagnosis from computational tomography (CT) scans, in addition to others that use patient medical
data to predict the evolution of the disease, as well as original non-invasivemeasurements which can
be used for monitoring purposes.
2.1 MEDICAL IMAGING FOR DIAGNOSIS
Reverse Transcription Polymerase Chain Reaction (RT-PCR) tests are the key approach used for
diagnosing COVID-19, however they have limitations in terms of specimen collection, time required
for the analysis, and performance (Ai et al., 2020). As such, there is growing interest in other
diagnostics methodologieswhich use medical imaging for the screening and diagnosis of COVID-19
cases (Kanne et al., 2020). It has been found that COVID-19 has particular radiological signatures
and image patterns which can be observed in CT scans (Ai et al., 2020). The identification of these
patterns is time-consuming even for expert radiologists. This makes diagnosis of COVID-19 from
lung CT scans of patients a good candidate for ML-based approaches, which could help accelerate
the analysis of these scans supporting specialists.
Several studies have addressed diagnosis as a binary classification problem, i.e. healthy vs. COVID-
19 positive. For example, Wang et al. (2020a)† use a modified Inception neural network architec-
ture (Szegedy et al., 2015) trained on regions of interest identified by radiologists to carry out binary
classification between healthy patients and those infected with COVID-19. Based on a dataset of
roughly 1,000 image slices from 259 patients, they were able to train a model capable of identifying
potential COVID-19 cases that could later be passed on to radiologists for further validation. Sim-
ilarly, Chen et al. (2020b)† found that by training a UNet++ neural network (Zhou et al., 2018) on
over 6,000 CT image slices of both healthy and infected patients labeled by expert radiologists, it
was possible to achieve performance comparable to that of an expert radiologist. The trained model
from this study was subsequently deployed at the Renmin Hospital of Wuhan University to help
radiologists accelerate the analysis of new cases, and open-sourced on the Internet to enable rapid
review of new images.
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Other ML approaches have framed the diagnosis problem as a 3-category classification task: distin-
guishing healthy patients from those with other types of pneumonia and those with COVID-19. In
both Xu et al. (2020)† and Song et al. (2020)† , classical ResNet architectures (He et al., 2016) are
used for feature extraction. Xu et al. (2020)† add several fully-connected layers for classification,
while Song et al. (2020)† add a Feature Pyramid Network (Lin et al., 2017) and attention module,
making the network more complex but also able to represent more fine-grained aspects of the im-
ages. Both of these studies show that even in cases where there are several competing potential
diagnoses, ML approaches have the potential to distinguish COVID-19 from other diseases with
similar symptoms.
Finally, some studies adopt a hybrid approach, combining off-the-shelf software with bespoke ML
approaches in order to achieve higher accuracy. For example, in Gozes et al. (2020)† a commer-
cial medical imaging program is used for initial image processing and then combined with an ML
pipeline. The two step ML approach consists of a U-Net architecture (Ronneberger et al., 2015)
trained on medical images of lung abnormalities in order to pinpoint lung regions of interest and a
Resnet-50 (He et al., 2016) trained on ImagetNet (Deng et al., 2009) and fine-tuned on COVID-19
cases in order to classify the images as Coronavirus or healthy.
Studies which report operational deployment, such as Shan et al. (2020)† , have adopted human-
in-the-loop approaches to reduce the labeling time required while utilizing ML architectures. The
authors use small manually-labelled batches of data for training an initial model based on the V-Net
architecture (Milletari et al., 2016). This model proposes segmentations of new CT scans, which can
then be corrected by radiologists and fed back into the model, in an iterative process. This approach
enabled the development of a Deep Learning-based system for both automatic segmentation and
counting of infection regions, as well as assessing the severity of COVID-19, e.g., the percentage of
infection in the whole lung. The authors show not only that the model improved its own performance
incrementally, but also that the human time required for analysis of new images dropped from over
30 minutes initially to under 5 minutes after 200 annotated examples were used to train the model,
reducing the effort required by radiologists to review a new scan. This is a promising direction which
harnesses the power of ML alongside human annotation and expertise, which can be complementary
and mutually beneficial.
2.2 NON-INVASIVE MEASUREMENTS FOR DISEASE TRACKING
Another original approach that does not require specialized medical imaging equipment uses footage
from Kinect depth cameras to identify respiratory patterns of patients (Wang et al., 2020b)† . This
is based on recent findings suggesting that COVID-19 has respiratory patterns which are dis-
tinct from those of the flu and common cold, notably that they exhibit tachypnea (rapid respira-
tion) (Cascella et al., 2020). Based on this information, the researchers developed a GRU neural
network (Cho et al., 2014) with bidirectional and attentional mechanisms to classify abnormal res-
piratory patterns, trained on both real world data from 20 participants and more abundant simulated
data generated based on the real recordings. While these abnormal respiratory patterns are not nec-
essarily correlated with real-world diagnosis of COVID-19, prediction of tachypnea could be a rele-
vant first-order diagnostic feature that may contribute to large-scale screening of potential patients.
Other proposals have also been made to utilize mobile phones in COVID-19 detection, either using
embedded sensors to identify COVID-19 symptoms (Maghdid et al., 2020)† or phone-based surveys
to filter high-risk patients based on responses to key questions (Rao & Vazquez, 2020); while these
are important efforts given the accessibility of mobile phone technology, the existing studies are not
sufficiently advanced to evaluate their feasibility and performance.
2.3 PATIENT OUTCOME PREDICTION
Yan et al. (2020)† propose a novel approach based on features contained in patients medical data and
blood tests to help clinicians identify high-risk patients as early as possible, thereby hopefully im-
proving the prognosis of all patients and reducing the mortality of those that are critically ill. Within
the scope of this study, a prediction model based on the XGBoost algorithm (Chen & Guestrin,
2016) was built to predict mortality risk and identify key measurable features which can be tested
for in hospitals. Based on data from 375 patients, the authors identified three key clinical indicators
(lactic dehydrogenase, lymphocyte and high-sensitivity C-reactive protein) from more than 300 in-
3
put features and thereby provide a clinical heuristic for estimating patient mortality. An advantage
of this approach is its interpretability, since the three indicators identified by the approach corre-
spond to the most important factors in the pathophysiological progress of COVID-19, namely: cell
injury, cellular immunity, and inflammation. A complementary study aimed to predict whether exist-
ing COVID-19 patients would require long-term hospitalization or not based on a U-Net derivative
trained on CT imaging data labeled semi-automatically (Qi et al., 2020)† . This means that once
initial diagnosis is established, it could also be possible to use ML to predict to what extent patients
conditions are liable to deteriorate and require long-term hospitalization. These two approaches can
help identify the patients that might require intensive and long-term care, helping hospitals manage
their resources more effectively. Finally, while both of these studies were limited in scope and data,
they constitute important avenues of research that can be complemented and extended with clinical
data from incoming cases around the world.
3 MOLECULAR SCALE: FROM PROTEINS TO DRUG DEVELOPMENT
Biochemistry applications of AI have also been used to better understand the proteins involved in
SARS-Cov-2 infection and to inform the search for potential treatments. With respect to the virus
itself, five types of structural proteins are of interest: nucleocapsid proteins (N), envelope proteins
(E), membrane proteins (M), and spike proteins (S) (Zhavoronkov et al., 2020b)† , (Liu et al., 2020)
and those not included in virion but that are translated in host cell and are crucial for viral repli-
cation (the nonstructural proteins, or nsp). Research has focused on one of these nsps (nsp5), the
3-chymotrypsin-like (3C-like) protease, an enzyme that assists in processing of viral proteins and
the replication of the virus. On the human side, research has focused on the angiotensin-converting
enzyme 2 (ACE2) protein, a receptor that facilitates the virus’ entry into host cells (Hoffmann et al.,
2020). Potential applications of AI include predicting the structure of these associated proteins,
identifying existing drugs which may be effective in targeting these proteins, and proposing new
chemical compounds for further testing as potential treatments (Zhavoronkov, 2018).
3.1 PROTEIN STRUCTURE PREDICTION
Proteins have a 3D structure, which is determined by their genetically encoded amino acid sequence,
and this structure influences the role and function of the protein (Senior et al., 2020a). Protein
structure is traditionally determined through experimental approaches such as X-ray crystallography,
but these can be costly and time-consuming. More recently, computational models have been used
to predict protein structure. There are two primary approaches to the prediction task: template
modeling, which predicts structure using similar proteins as a template sequence, and template-free
modeling, which predicts structure for proteins that have no known related structure.
Senior et al. (2020b) have developed a system called AlphaFold which focuses on the latter chal-
lenge. The AlphaFoldmodel is based on a dilated ResNet architecture (He et al., 2016; Yu & Koltun,
2016) and uses amino acid sequences, as well as features extracted from similar amino acid se-
quences using multiple sequence alignment, to predict the distance and the distribution of angles
between amino acid residues. These predictions are used to construct a “potential of mean force”
which can be used to characterize the protein’s shape (Senior et al., 2019). This system has been
applied to predict the structures of six proteins related to SARS-CoV-2 (SARS-CoV-2 membrane
protein, protein 3a, Nsp2, Nsp4, Nsp6, and papain-like proteinase) (Jumper et al., 2020).
3.2 IMPROVING VIRAL DNA TESTING
There are also efforts to use Machine Learning and novel genome technologies to improve the cur-
rent RT-PCR test. Metsky et al. (2020)† use CRISPR (a tool which uses an enzyme to edit genomes
by cleaving specific strands of genetic code) to develop assay designs for detecting 67 respiratory
viruses, including SARS-CoV-2. The authors note that this technology can speed up the processing
of test samples in order to assist overburdened diagnostic facilities, and help address the challenge of
false positives which occur as a result of sequence similarity between SARS-Cov-2 and other coro-
naviruses. ML models have been built to rapidly design assays which are predicted to be sensitive
and specific, and cover a diverse range of genomes. The authors state that they are aiming to build a
Cas13-based point-of-care assay for SARS-CoV-2 in the future.
4
3.3 DRUG REPURPOSING
One approach to discovering existing drugs which could be repurposed to treat COVID-19 is the
use of biomedical knowledge graphs. Biomedical knowledge graphs are networks capturing the
relationships between different entities – such as proteins and drugs – in order to facilitate higher-
level exploration of how they connect to each other. Richardson et al. (2020) use this technique
to identify Baricitinib, a drug which is commonly used to treat arthritis via inhibition of JAK1/2
kinases, as a promising therapy for COVID-19 because it inhibits the AP2-associated protein kinase
1 (AAK1) enzyme and may therefore make it harder for the virus to enter host cells. Related work
has described two approaches which potentially inform the graph construction. First, Segler et al.
(2018) describe an approach to mining a structured database of chemical reactions (Reaxys) using a
three-part neural network pipeline combined with a Monte Carlo Tree Search approach (3N-MCTS),
in order to understand how various compounds are formed hierarchically from reactions between
simpler component compounds. Second, Fauqueur et al. (2019) describe a strategy for mining an
unstructured scientific article database (PubMed) to identify stylized relationships between gene-
disease pairs expressed in individual sentences (e.g. “GENE promotes DISEASE”).
Ge et al. (2020)† describe a similar approach to constructing a knowledge graph connecting human
proteins, viral proteins, and drugs using databases which capture the relationships between these
entities. The graph is used to predict potentially effective candidate drugs. This list is further
refined using a Natural Language Processing (NLP) model (a Biomedical Entity Relation Extraction
(BERE) approach (Hong et al., 2019)† ) applied to the PubMed database, filtered for mentions of
the candidate drug compounds, coronaviruses, or their associated proteins. The authors identify a
Poly (ADP-Ribose) Polymerase 1 (PARP1) inhibitor, CVL218, as a promising candidate, and it is
currently undergoing clinical testing.
Other studies use models developed to predict protein-ligand binding affinities in order to tackle
the drug repurposing problem. Ligands are small molecules which bind with a protein to trigger a
signal, which can be activation or inhibition. Hu et al. (2020a)† use a multi-task neural network for
the general prediction of these affinities. The authors identify a list of SARS-CoV-2 related proteins
(RNA-dependent RNA polymerase, 3C-like protease, papain-like protease, helicase, spike glycopro-
tein, exonuclease, endoRNAse, 2’-O-ribose methyltransferase, and envelope protein), which they
attempt to target using a database of 4,895 drugs. They suggest 10 promising drugs, along with their
target proteins and binding affinity scores (which indicate the likelihood that the drug will act as an
inhibitor). In an attempt to increase model interpretability, they also estimate the precise regions
of each target protein where binding is likely to occur. In a similar vein, Beck et al. (2020)† use
their own Molecule Transformer-Drug Target Interaction (MT-DTI) model (Shin et al., 2019) of
binding affinities to identify US Food and Drug Administration (FDA) approved antivirals which
may be effective in targeting six coronavirus-related proteins (3C-like protease, RNA-dependent
RNA polymerase, helicase, 3’-to-5’ exonuclease, endoRNAse, and 2’-O-ribose methyltransferase).
The MT-DTI model ingests string data in the form of simplified molecular-input line-entry system
(SMILES) data and amino acid sequences, and applies a text-modeling approach that leverages ideas
from the BERT algorithm (Devlin et al., 2018). The model identifies drugs that are expected to be
effective in targeting each protein studied. Finally, Zhang et al. (2020)† use a dense fully connected
neural network, trained to predict binding affinities on the PDBBind database, in order to identify
potential inhibitors of the 3C-like protease. They develop a homology (template) model of the target
protein using its SARS variant, and explore databases of existing compounds (e.g. ChemDiv and
TargetMol) as well as tripeptides to find treatments which may be effective at targeting this protein.
3.4 DRUG DISCOVERY
There is also some research that attempts to discover novel compounds for use in targeting SARS-
Cov-2. Zhavoronkov et al. (2020a)† use a proprietary pipeline to find inhibitors for the 3C-like pro-
tease. Their models use three types of input: the crystal structure of the protein, the co-crystalized
ligands, and the homology model of the protein. For each input type, the authors fit 28 differ-
ent models including Generative Autoencoders (Makhzani et al., 2015) and Generative Adversarial
Networks (Goodfellow et al., 2014). The authors explore potential candidates using a reinforcement
learning approachwith a reward function that incorporates factors such as measures of drug-likeness,
novelty, and diversity. Moreover, they confirm that the identified candidate molecules are dissimilar
to existing compounds, suggesting that they have indeed found novel candidate drugs.
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Tang et al. (2020)† also apply a reinforcement learning approach to the discovery of compounds
that inhibit the 3C-like protease. Specifically, the authors create a list of 284 molecules known to
act as inhibitors in the context of SARS. They break these proteins into a series of 316 fragments,
which can then be combined using an advanced deep Q-learning network with fragment-based drug
design (ADQN-FBDD) which rewards three aspects of discovered molecules: a drug-likeness score,
the inclusion of pre-determined “favorable” fragments, and the presence of known pharmacophores
(which are are essentially abstract design patterns believed to be correlated with a compound’s effec-
tiveness (Qing et al., 2014)). The 4,922 results are heuristically filtered and the 47 top compounds
assessed with molecular docking simulations, from which the researchers then select the top most
promising compound and manually tailor it to produce suggested variants for testing.
4 SOCIETAL SCALE: EPIDEMIOLOGY AND INFODEMIOLOGY
4.1 EPIDEMIOLOGY
The spread of SARS-CoV-2 across the globe has received much policy attention, with advice at the
national and local level changing daily in many locations as new information and model forecasts
become available. Understanding how the virus is transmitted, and its likely effect on different
demographics and geographic locations, is crucial for public policy healthcare interventions.
The field of epidemiological research is incredibly vast, and the relevance and scale of the pandemic,
in addition to new data becoming available, has resulted in multiple modelling efforts. While most of
the modeling endeavours develop on well-established classical models such as susceptible-infected-
recovered (SIR) models and fine-tune them to the COVID-19 situation, we focus here on cases
specifically employing Machine Learning techniques for epidemiological modeling tasks.
Given the rapid progression of infections, real-time short-term forecasting can be a vital source of
information. In particular, models must be flexible in order to adapt to changing protocols and pro-
cedures. Hu et al. (2020b)† have compiled data collected by World Health Organization (WHO) and
other actors across the period from January 11 - February 27, 2020 to develop a dataset of accumu-
lated and new confirmed cases in 31 provinces and cities of China. This information is used to train
a modified auto-encoder (MAE) for real-time forecasting of new cases, and may be used to estimate
the extent and duration of the epidemic. Models can be trained at the city, provincial, or national
level. Furthermore, the authors extract information from the auto-encoder’s latent variable layers
to determine the model’s most important features for each analysed region. These features are then
fed into a k-means clustering algorithm that groups similar regions for further analysis. The hope is
that this final step will enable more efficient investigation in the regions showing infected/recovered
characteristics of interest.
Similarly, Al-qaness et al. (2020) propose a new forecasting model for predicting the total number
of confirmed cases ten days in advance, using historical data. The authors base their model on
an adaptive neuro-fuzzy inference system (ANFIS) (Jang, 1993), along with an enhanced flower
pollination algorithm (FPA) (Yang, 2012) and salp swarm algorithm (SSA) (Mirjalili et al., 2017) to
optimize the parameters of the model. The resulting ANFIS-FPASSA model is optimised according
to the mean-squared error on data collected from the WHO’s published daily confirmed cases in
China. Given the short-term nature of the WHO data, the authors also test the robustness of their
approach by training and testing on weekly confirmed influenza cases as collected by the US Centre
for Disease Control and the WHO over two different four-year periods. In all three cases the authors
found their model to outperform similar ANFIS models trained using other methods for parameter
setting.
A more specific use of ML methods is employed by Mizumoto et al. (2020) who seek to understand
the rate of asymptomatic cases using data collected from the COVID-19 outbreak on-board the
Diamond Princess cruise ship. Here, asymptomatic is defined as a patient who has tested positive
for the virus but is not displaying any symptoms at the time of testing. In this work, the authors
use time-series data collected at different test times up until two days after the scheduled quarantine
ended on February 21, 2020. In total, the dataset contained 634 confirmed cases and the proportion
of asymptomatic patients at different time stamps. Using this data the authors modelled the time-
series using a Bayesian analysis technique, with HamiltonianMonte Carlo (HMC) and a No-U-Turn-
Sampler (Homan & Gelman, 2014) used for model parameter estimation, to estimate the probability
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of a given patient being asymptomatic given infection, along with the duration an individual is
infected for. Using point estimates from the posterior, the authors estimated that asymptomatic
proportion of individuals was 17.9% at the level of the 95% credible interval. Whether this study
can be extrapolated to the wider population has yet to be seen, although analysis from contained
environments such as this one could be of great importance.
4.2 INFODEMIOLOGY
While not specifically an application of AI, we feel it prudent to discuss the current impact of the
recent “infodemic” being experienced around the world. In this section we highlight work being
carried out to quantify the spread of information surrounding the pandemic, and understand its
dynamics. Moreover, dealing with this vast amount of information requires the development and
adoption of new tools, particularly surrounding the dissemination of misinformation. While this is
already an area in which much AI and, more specifically ML, research has been carried out, there
is still a need for greater understanding of the underlying social dynamics. This is of particular
importance in times such as these, in which vital information needs to be able to cut through the
noise to prevent loss of life.
Social media and online platforms have become key distribution channels for information surround-
ing the virus. Although national and international organizations have used these platforms to con-
structively communicate with the public, we are also seeing an infodemic in which populations can
become overwhelmed with information, and the propagation of misinformation or mis-informed in-
formation is increasingly prevalent. Zarocostas (2020) highlight the WHO’s response to combating
this infodemic through the use of its Information Network for Epidemics (EPI-WIN) platform for
sharing information with key stakeholders. Additionally, the WHO is also working with social me-
dia and search companies to track the spread of specific rumors and to ensure that WHO content is
displayed at the top of searches for terms related to the virus.
In a broad-ranging study, Cinelli et al. (2020)† analyze interaction and engagement with COVID-
19-related social media content. The authors collected eight million comments and posts, selected
using COVID-19 related keywords, posted between January 1 and February 14, 2020 from Twitter,
Instagram, YouTube, Reddit and Gab. The authors estimate engagement and interest in COVID-19
and comparatively assess the evolution of discourse on each platform. Interaction and engagement
are measured using the cumulative number of posts, and the number of reactions (e.g. comments,
likes etc.) to these posts across the 45-day period. The authors then employed phenomenological
(Fisman et al., 2013) and classical SIR models to characterize the reproduction numbers. Specifi-
cally, they examine the average number of secondary cases (users that start posting about COVID-
19) created by an “infectious” individual (already posting) on each of the social media platforms. As
in epidemiological models, the authors simulate the likelihood of an infodemic in which discussion
of COVID-19 will grow exponentially, at least in its initial stages. Moreover, the authors examine
the spread of misinformation (which they identify using external fact-checking organizations). The
authors find that information from both reliable and unreliable sources propagate in similar pat-
terns, but that user engagement with posts from less-reliable sources is lower than engagement with
content from reliable sources on major social media streams.
Similarly, Mejova & Kalimeri (2020)† have examined the use of Facebook advertisements with con-
tent related to the virus. The authors used the Facebook Ad Library to search for all advertisements
using the keywords “coronavirus” and “covid-19” and collected 923 results across 34 countries,
with most in the US (39%) and the EU (Italy made up 25% of the advertisement markets). While
the majority of adverts were found to be paid for by non-profits to disseminate information and so-
licit donations, the authors found that around 5% of advertisements contained possible erroneous or
misinformation.
Finally, efforts are underway to curate specific news content related to the virus and perform both
manual and automated fact-checking and relevance analysis. Pandey et al. (2020)† have developed
a pipeline for assessing the similarity between daily news headlines and WHO recommendations.
The pipeline uses word embedding and similarity metrics, such as cosine similarity, to assess the
relevance level ofWHO recommendations to news article titles and content. If the similarity is above
a certain threshold then the new article displays on the user’s timeline with the associated relevant
WHO recommendation. The setting of the similarity threshold is determined by human reviewers
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prior to release and then can be updated through user feedback. In the face of conflicting information,
such methods could help identify accurate and trustworthy news articles which highlight important
guidelines and promote official recommendations.
5 DATASETS AND RESOURCES
The success of the global effort to use AI techniques to address the COVID-19 pandemic hinges upon
sufficient access to data. Machine Learning, and Deep Learning in particular, requires notoriously
large amounts of data and computing power in order to develop and train new algorithms and neural
network architectures. In this section, we describe some of the datasets and data collection efforts
that exist at the present time.
5.1 CASE DATA
The current number and location of cases is essential for tracking the progress of the COVID-
19 pandemic in different locations, calculating the growth factor of new infections, and observ-
ing the impact of preventative measures. Several datasets from organizations such as the WHO
and national centers for disease control (CDCs) exist for this purpose, and they have been ag-
gregated into public repositories hosted by institutions such as Johns Hopkins CSSE and crowd-
sourced efforts on platforms like Github, in order provide day-level information on COVID-19
affected cases gathered from a variety of reliable sources. There are also other complementary
data sources including regional data as school closures, bank interest rates, and even community
perceptions of the virus, many of which are continuously being added to a data portal hosted by
the Humanitarian Data Exchange. There are a multitude of AI algorithms that can be applied on
this kind of data, ranging from time series forecasting approaches such as Auto Regressive Inte-
grated Moving Average (ARIMA) to other regression approaches. Given a sufficient quantity of
data and features, neural network architectures such as Long-Short Term Memory (LSTM) net-
works (Hochreiter & Schmidhuber, 1997) could also be applied to predict the evolution of cases on
a global and regional scale.
There are also some tools and resources that are being developed specifically for medical profes-
sionals and institutions. For instance, CHIME is an open-source COVID-19 Hospital Impact Model
for Epidemics based on SIR modeling, which uses the number of susceptible, infectious, and re-
covered individuals to compute the theoretical number of people infected over time and to predict
outcomes in specific circumstances. While this project is currently not using any ML techniques, it
could certainly benefit from these techniques in order to be able to incorporate more features and
data points, and therefore to improve prediction quality. There are also efforts being made to use
de-identified, large-scale data assess mobility changes and their impact on the local unfolding of the
epidemic, for instance by the COVID19 MM working group in Italy.
5.2 TEXTUAL DATA
NLP approaches in particular can be extremely useful, given the vast quantity of textual information
that exists regarding COVID-19 and other coronaviruses. These can be used to answer key research
questions such as:
1. What is known about the virus’ transmission, incubation, and environmental stability?
2. What do we know about COVID-19 risk factors?
3. What do we know about non-pharmaceutical interventions?
4. What do we know about vaccines and therapeutics?
5. What has been published about ethical and social science considerations?
6. What has been published about medical care?
These questions can be analyzed using different sources, such as articles from the
WHO Global Research Database on COVID-19, a curated literature hub for COVID- 19 scien-
tific information, and the COVID-19 Open Research Dataset (CORD-19), the current largest open
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dataset available with over 29,000 research articles about COVID-19, SARS-CoV-2, and other coro-
naviruses. There are already several ongoing Kaggle challenges involving this data, with dozens of
questions submitted daily and many teams involved. There are also several other scientific research
datasets that can be exploited, including LitCOVID and the Dimensions AI COVID-19 dataset,
which contain supplementary information regarding datasets and clinical trial data when available.
The textual data from scientific articles can also be completed with data from other sources, such
as social media. For instance, several public Twitter datasets (such as COVID-19 TweetIDs and
Covid19 Tweets) have recently been released, which are maintained based on coronavirus-related
tweets.
Using any of the sources mentioned above, NLP techniques can be applied to develop text mining
tools that can help the medical community find answers to key scientific questions regarding the
nature and progress of COVID-19. Different NLP and Information Retrieval (IR) methods could
be utilized to glean relevant information from these rich sources of data, including out-of-the-box
toolkits like SciSpacy, a text processing toolkit optimized for scientific text, and SciBERT, a pow-
erful universal NLP model that can be used to represent scientific texts and to carry out tasks like
summarization, question answering, and the retrieval of relevant passages. Social media sources
could also be used to enhance scientific literature-based approaches, to help track misinformation
and unverified rumors, or to enable the monitoring of population reactions to the virus on social
media (Chen et al., 2020a).
5.3 BIOMEDICAL DATA
At the current moment, there are not many open-source datasets and models for diagnostic purposes.
Some of the CT scan detection approaches described in Section 2 are available online and accessible
to the public, for instance those of Wang et al. and Song et al. However, the data used to train
the various models described is not systematically shared, which would be of great value to the
ML research community. Initiatives like the Covid Chest X-Ray Dataset are aiming to build such a
dataset with a crowdsourced approach, but are slow to put together and maintain manually. Also,
while data collection andMLmodel training can be carried out by computer scientists, data labelling
and annotation often need to be done bymedical professionals such as radiologists or clinicians. This
is why projects such as Data Against Covid are particularly important – they aim to bring together
the medical community, who have data regarding the COVID-19 crisis, with data scientists and ML
experts who can help them extract insights and actionable information from this data. These kinds
of initiatives are promising given their potential to bridge the gap between those with medical and
biological knowledge and experience and those with data skills.
In terms of genomic sequencing and drug discovery, there are several datasets based on pre-existing
initiatives or created from scratch for COVID-19 specifically. In fact, tracking the genome sequence
of SARS-CoV-2 is crucial to design and evaluate diagnostic tests, to track and trace the pandemic,
and to identify the most promising intervention options. Notably, the GISAID Initiative, founded
over a decade ago for the specific purpose of promoting the international sharing of influenza virus
sequences and related clinical and epidemiological data, is tracking the genomic epidemiology of
SARS-CoV-2. Furthermore, other well-established initiatives such as the RCSB Protein Data Bank
and the Global Health Drug Discovery Institute also have centralized portals with data and resources
for different aspects of understanding COVID-19 and for carrying out structure-guided drug discov-
ery. Nextstrain is an open-source project looking at genetic diversity of coronaviruses to character-
ize the geographic spread of COVID-19 by inferring the lineage tree of hundreds of publicly shared
genomes of SARS-CoV-2. Another interesting resource is the citizen science game Fold.it which
leverages collective intelligence against COVID-19 by proposing to design an antiviral protein.
6 DISCUSSION
As seen in this research mapping exercise, ML and AI can support the response against COVID-19
in a broad set of domains. In particular, we have highlighted emerging applications in diagnosis,
clinical outcome prediction, drug discovery and development, epidemiology, and infodemiology.
However, we note that very few of the reviewed systems have operational maturity at this stage. In
order to operationalize this research, it is important to define a research road map and a funnel for
AI applications to understand how this technology can immediately assist with the response, how it
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might help later on in the evolution of the current pandemic, and how it can be used to combat future
pandemics. As members of a global community of researchers and data scientists, we identify three
key calls for action.
First, we believe that scalable approaches to data sharing using open repositories will drastically
accelerate the development of new models and unlock data for the public interest. Image-based
medical diagnosis, in particular, is a domain in which training data is currently scarce but the value
of AI models may be high. In order to facilitate the sharing of such data, clinical protocols and
data sharing mechanisms will need to be designed and data governance frameworks will need to be
put in place. It is important to reinforce that research with medical data must be subject to strong
regulatory requirements and privacy protecting mechanisms. Overall, any AI application developed
should undergo an assessment to ensure that complies with ethical principles and above all respects
human rights.
Second, the multidisciplinary nature of the research required to deploy AI systems in this context
calls for the creation of extremely diverse, complementary teams and long-term partnerships. Be-
yond the examples shown in this review, other promising domains in which AI could be used to
fight against COVID-19 include robotics (e.g. cleaning or disinfecting robots) and logistics (e.g. the
allocation and distribution of personal protective equipment). Funding opportunities which encour-
age such collaborations and define key research directions may help accelerate the success of such
partnerships.
Third, we believe that open science and international cooperation can play an important role in
this pandemic – in particular to prepare the regions which have not yet experienced widespread
outbreaks, as well as to improve the resilience of health systems, which are currently under tremen-
dous stress across all dimensions. In the face of healthcare capacity being overstretched, we must
strengthen our health systems to sustain services beyond the control and management of COVID-19
to truly protect the vulnerable, such as people living with noncommunicable diseases (NCDs). AI
systems, methods, and models can act as a compact form of knowledge sharing which can be used to
train other specialists, or shared directly if they are designed to be widely deployable. In particular,
given that many private sector companies and AI partnerships operate across international borders,
they may be in position to facilitate the knowledge dissemination and capacity building of national
health systems.
We acknowledge the difficulty of adding value through AI in the current situation. Nevertheless, we
hope that this review is a first step towards helping the AI community understand where it can be
of value, which are the promising domains for collaboration, and how research agendas can be best
directed towards action against this or the next pandemic.
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